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Summary We analyzed the effect of combination therapy on seizure frequency in
all adult patients (N = 193) with focal epilepsy followed at a single institution in a
cross-sectional study. One hundred and thirty-five patients were on two AEDs, of
them, 37 (27%) were seizure-free, 50 patients were on three AEDs including 5 (10%)
seizure-free patients ( p < 0.01 for seizure-freedom with two AEDs versus three
AEDs). Thirty-five different combinations were used in patients on two AEDs and
40 combinations on patients on three drugs emphasizing the difficulties involved in
evaluation of the efficacy and tolerability of specific combinations. The significant
proportion of seizure-free cases (27%) on duotherapy is suggesting the usefulness of
combination therapy in achieving seizure-freedom in epilepsies refractory to single
drug treatment. The material in the study was not from a randomized trial and
therefore the comparability of patients on different AEDs is uncertain, but on the
other hand the clinical practice followed provides a natural experiment suitable for
comparative, non-randomized assessment of treatment outcomes.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Approximately 50% of the adult newly diagnosed
patients with epilepsy reach seizure-freedom with
the use of the first antiepileptic drug (AED), whereas
only 10% respond to the second AED monotherapy.1
If the first or second monotherapy improves control* Corresponding author. Tel.: +358 407022987;
fax: +358 331164351.
E-mail address: jukka.peltola@pshp.fi (J. Peltola).
1059-1311/$ — see front matter # 2007 British Epilepsy Association
doi:10.1016/j.seizure.2007.08.001of the seizures but does not produce seizure-free-
dom the use of combination therapy has been advo-
cated.2 Combination therapy has been found to be
successful in about 30% of patients.3,4 A recent
randomized study comparing combination therapy
and alternative monotherapy in patients failing on a
single AED found no difference in the success rates
of the therapies.5
With the introduction of new AEDs the number of
possible combinations of two or more drugs has
increaseddramatically. Thereare somecombinations. Published by Elsevier Ltd. All rights reserved.
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gism such as lamotrigine/valproate.6 Some other
combinations are judged beneficial on the bases of
their complimentary mechanisms of actions without
clinical data.2 Generally, there is scarcity of evidence
about effective combinations, and the new wave of
polytherapy has also raised concerns of overtreat-
ment of epilepsy.7
We have analyzed the effect of combination
therapy on seizure frequency in all adult patients
with focal epilepsy, the most common refractory
form of epilepsy, followed at a single institution,
where the majority of therapy resistant patients of
Pirkanmaa region (population of 440,000) are trea-
ted; only elderly patients and patients with mental
retardation are treated elsewhere. Thus though not
strictly population based our patient group probably
represents the general population with refractory
epilepsy.Methods
Patients
All patients with focal epilepsy followed at Tampere
University Hospital 30.9.2004 were identified from
the hospital patient registry using ICD-10 diagnostic
codes for focal epilepsy (G40.1 and G40.2). AlsoTable 1 Clinical characteristics of patients with combinat
Characteristics Num
2
Total (n) 135
Sex
Male (%) 45
Female (%) 55
Mean age (S.D.) 43.
Type of epilepsy
Temporal lobe epilepsy (%) 44
Frontal lobe epilepsy (%) 24
Parieto/occipital epilepsy (%) 10
Multifocal epilepsy (%) 3
Unclassifiable (%) 19
Mean duration of epilepsy (years) (S.D.) a 21.
Etiologyb
Cryptogenic (%) 34
Remote symptomatic (%) 66
Seizure frequency (during the previous year) c
Seizure-free (%) 27
Persistent seizures (%) 73
a Missing information: 2 in 2 AED.
b Missing information: 5 in 2 AED, 1 in 3 AED and 1 in 4 AED.
c Missing information: 3 in 2 AED.patients with the diagnosis number of G40.9 (Epi-
lepsy, unspecified) were screened. The study was
approved by the Ethics Committee of the Tampere
University Hospital. Patients with combination ther-
apy were included for the present study. The infor-
mation of patient characteristics was obtained from
the medical records. The patients were classified
according to ILAE guidelines to8 temporal lobe epi-
lepsy, frontal lobe epilepsy, parietal/occipital lobe
epilepsy, multifocal epilepsy and unclassifiable
based of seizure characteristics, EEG and imaging
findings, and in some patients on ictal video-EEG
recordings. The etiologies were divided into remote
symptomatic and cryptogenic. The mean monthly
seizure frequency during the previous year was
recorded; seizure-free patients did not have any
seizures during the previous year. The AEDs cur-
rently used, information on doses and duration of
the present regimen were registered.
Statistical methods
When comparing proportion of seizure-free patients
with different number of AEDs, statistical signifi-
cance was assessed using a chi-square test. Logistic
regression methods were used in multivariate ana-
lyses, with persistent seizures as the outcome. Expla-
natory variables included gender, epilepsy type
(temporal, frontal, parieto—occipital, multifocal),ion therapy
ber of current antiepileptic drug (AED)
3 4
50 8
60 50
40 50
4 (14.3) 37.6 (13.0) 36.7 (13.6)
48 75
42 13
— —
8 13
2 —
2 (15.5) 25.4 (13.5) 17.3 (12.0)
47 14
53 86
10 —
90 100
278 J. Peltola et al.duration of epilepsy (years) and etiology (remote
symptomatic versus cryptogenic) as cofactors. Con-
fidence intervals shown are likelihood-based, and the
Newton—Raphsonmethod is used to obtainmaximum
likelihood parameter estimates.Results
Altogether 395 patients with localization-related
epilepsy were identified from computerized patient
database. Two hundred and two patients were on
monotherapy and were excluded from this study
with remaining 193 patients on combination ther-
apy. The most common epilepsy type was temporal
lobe epilepsy (42%, N = 81), 50 (26%) patients had
frontal lobe epilepsy, 13 (7%) parieto—occipital epi-
lepsy and 8 (4%) patients multifocal epilepsy
(Table 1). One hundred and thirty-five patients were
on two AEDs, of them, 37 (27%) were seizure-free,
50 patients were on three AEDs including 5 (10%)
seizure-free patients ( p < 0.01 for seizure-freedom
with two AEDs versus three AEDs). All 8 patients on
four AEDs had recurrent seizures (Table 1). In logistic
regression analysis patients on three or four drugs
had 4.5 times (95% confidence interval 1.57—12.9)
higher risk for persistent seizures when compared
with patients on two drugs. Table 2 shows the
clinical characteristics of seizure-free patients.
Patients (N = 135) with duotherapy had 35 differ-
ent combinations of AEDs, and the most common
combinations were lamotrigine—valproate (N = 19),
carbamazepine—topiramate (N = 15), oxcarbaze-
pine—topiramate (N = 10), oxcarbazepine—levetir-Table 2 Clinical characteristics of seizure-free patients co
Seizure-free
2 Antiepileptic drugs (AED) 88%
3 AED/4 AED 12%
Age 43.1c
Male 48%
Female 52%
Type of epilepsy
Temporal lobe epilepsy 50%
Frontal lobe epilepsy 24%
Parieto/occipital epilepsy 5%
Multifocal epilepsy 2%
Unclassifiable 19%
Duration of epilepsy (years) a 21.7c
Etiologyb
Remote symptomatic 58%
Cryptogenic 43%
Number of previously tried new AEDs 0.7c
a Missing information: 1 in seizure-free, 1 in persistent seizures.
b Missing information: 2 in seizure-free, 5 in persistent seizures.
c Mean.acetam (N = 9) and carbamazepine—tiagabine
(N = 9). For the purpose of analysis sodium channel
blockers [carbamazepine (N = 48)/oxcarbazepine
(N = 38)/phenytoin (N = 3) (CBZ/OXC/PHT)] were
lumped together (Table 3). The individual combina-
tions with most seizure-free patients were lamotri-
gine—valproate (N = 5), CBZ/OXC/PHT-topiramate
(N = 5), CBZ/OXC/PHT—gabapentin (N = 5), CBZ/
OXC/PHT—lamotrigine (N = 4), CBZ/OXC/PHT—
levetiracetam (N = 3) and lamotrigine—levetirace-
tam (N = 3). The patients (N = 50) with three AEDs
had 30 different combinations with only one com-
bination (lamotrigine/topiramate/valproate) with
more than five (N = 7) patients. The mean and med-
ian doses of the most common combinations are
described in Table 4.Discussion
The majority of patients with newly diagnosed epi-
lepsy remain seizure-free with their first or second
monotherapy,1 and combinations of AEDs are usually
prescribed in those unresponsive to monotherapy.2
Our patients represent typical refractory focal epi-
lepsies with high proportion of temporal lobe epi-
lepsy and remote symptomatic etiology. In this
group, seizure-freedomwas achieved in a significant
proportion of cases (27%) on duotherapy suggesting
the usefulness of combination therapy in achieving
seizure-freedom in epilepsies refractory to single
drug treatment. A recent outcome study on newly
diagnosed epilepsy had given a 29% response rate to
two-drug combinations3 whereas in the originalmpared with patients with persistent seizures
Persistent seizures OR 95%CI
64% 1.00
36% 4.22 1.45—12.3
41.1c 1.00 0.97—1.03
49% 1.00
51% 1.24 0.56—2.71
45% 1.00
30% 1.45 0.59—3.58
8% 2.71 0.51—14.3
5% 0.83 0.08—9.02
13% 1.79 0.54—5.86
22.3c 0.98 0.95—1.02
65% 1.00
35% 0.68 0.31—1.49
1.2c 1.52 1.03—2.25
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Table 3 The number of patients with two drug combinations (sodium channel blockers combined to a single group, 35
different combinations)
CBZ/OXC/PHTa Lamotrigine Valproate Topiramate
Topiramate 25 7 0 —
Levetiracetam 15 5 1 3
Tiagabine 13 5 1 0
Gabapentin 10 2 0 1
Lamotrigine 6 — 19 7
Clobazam 6 0 0 0
Clonazepam 5 0 1 0
Valproate 3 19 — 0
Phenobarbital 2 0 0 0
Primidone 1 0 0 0
Retigabine 1 0 0 0
Vigabatrin 1 0 0 0
a Carbamazepine/oxcarbazepine/phenytoin.report only 3% of patients achieved seizure-freedom
with treatment with two drugs.1 Only 10% of our
patients with three drugs achieved seizure-freedom
and none of the patients with four drugs were totally
controlled.
The material in the study was not from a rando-
mized trial and therefore the comparability of
patients on different AEDs is uncertain. Further-
more, this was a cross-sectional study, so the
patients had a variable history in terms of the
duration of epilepsy and time since first contact
to the study hospital. Homogeneity of patient popu-
lation was increased by restriction of analyses to the
patients with focal epilepsy treated with combina-
tion therapy at a single centre. Yet, the lack of a
uniform treatment guideline actually helps the
assessment of different AEDs, as the variability in
the order in which AEDs are introduced improvesTable 4 The doses (mg/day) of individual antiepileptic dr
Two AED combinations
N Mean Median
Carbamazepine 48 919 850
Oxcarbazepine 38 1398 1350
Topiramate 36 291 300
Lamotrigine with valproic acid 19 150 150
Lamotrigine without valproic acid 25 336 400
Valproate 25 1316 1500
Levetiracetam 24 1688 1000
Tiagabine 19 34 30
Gabapentin 14 2457 2600
Clonazepam 7 1.8 1.5
Clobazam 6 15 15
Phenytoin 4 288 275
Phenobarbital 2 125 125
Primidone 1 500 500
Retigabine 1 300 300
Vigabatrin 1 2000 2000comparability between the combinations relative to
a fixed sequence of medications. Thus, the clinical
practice followed provides a natural experiment
suitable for comparative, non-randomized assess-
ment of treatment outcomes.
Over the past decade 10 new AEDs have been
introduced worldwide increasing the number of
possible combinations substantially. In our study
35 different combinations were used in patients
on two AEDs and 40 combinations on patients on
three drugs emphasizing the difficulties involved in
evaluation of the efficacy and tolerability of specific
combinations. Several combinations in our study
gave seizure-freedom and direct comparison
between different combinations is difficult because
new AEDs have been introduced in different time
points. Lamotrigine came to market in Finland 1994,
gabepentin 1995, tiagabine and topiramate 1999ugs (AEDs)
Three or four AED combinations
Range N Mean Median Range
300—1650 19 876 800 450—1500
600—2100 10 1290 1200 600—1800
50—600 29 278 300 25—550
75—250 16 188 200 100—250
200—500 12 408 400 200—700
200—2500 19 1316 1500 100—2000
1000—3000 29 2172 2000 1000—3000
15—70 9 31 30 20—45
800—3600 8 2575 2400 1600—3600
1—5 7 8.8 3 1—45
10—25 21 20 20 5—40
200—400 1 300 300 300—300
100—150 1 150 150 150—150
500—500 — — — —
300—300 — — — —
2000—2000 — — — —
280 J. Peltola et al.and levetiracetam 2001, whereas pregabalin and
zonisamide were not licensed at the time of the
investigations. In a previous study on combination
therapy the regimen of lamotrigine and sodium
valproate was the most common combination in
patients with localization-related epilepsy achiev-
ing seizure-freedom followed by combinations of
phenytoin and phenobarbital, carbamazepine and
gabapentin and carbamazepine and sodium valpro-
ate.9 In our study the most common individual
combination was lamotrigine and valproate as well,
but other common combinations were sodium chan-
nel blocker and topiramate or levetiracetam or
tiagabine or gabapentin demonstrating usual pat-
terns of combining a sodium channel blocker with a
new AED with different mode of action (rational
polytherapy). We were not able to identify any of
the combinations more successful than the others.
In general, the median doses in our study were
comparable to suggested target doses formostAEDs.7
Very little known about optimal doses in combination
therapy and there is a danger of using unnecessarily
high doses leading to over-treatment.7 Although only
10% of patients on three drugs achieved seizure-free-
dom there may be other clinical benefits obtained
with combining threedrugs such as changes in seizure
types (disappearance of tonic—clonic seizures) and
diurnal patterns of seizures.
At present the selection of combination therapy
is based more on speculation than on the bases of
clinical evidence.10 In future studies the utility of
combinations of two drugs versus three drugs should
be evaluated, as well as the use of most common
combinations in selected patient populations, for
instance, frontal lobe seizures and combination of
lamotrigine and valproate.11 Also evaluation of the
benefits of successive trials of new AEDs should be
addressed.Acknowledgement
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